![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Maher, Toby M.; Brown, Kevin K.; Kreuter, Michael; Devaraj, Anand; Walsh, Simon L. F.; Lancaster, Lisa H.; Belloli, Elizabeth A.; Padilla, Maria; Behr, Jürgen; Goeldner, Rainer-Georg; Tetzlaff, Kay; Schlenker-Herceg, Rozsa und Flaherty, Kevin R.
(2022):
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
In: European Respiratory Journal, Bd. 59, Nr. 2, 2004587
2020
de Bono, Johann; Lin, Chia-Chi; Chen, Li-Tzong; Corral, Jesus; Michalarea, Vasiliki; Rihawi, Karim; Ong, Michael; Lee, Jih-Hsiang; Hsu, Chih-Hung; Yang, James Chih-Hsin; Shiah, Her-Shyong; Yen, Chia-Jui; Anthoney, Alan; Jove, Maria; Buschke, Susanne; Fuertig, Rene; Schmid, Ulrike; Goeldner, Rainer-Georg; Strelkowa, Natalja; Huang, Dennis Chin-Lun; Bogenrieder, Thomas; Twelves, Chris und Cheng, Ann-Lii
(2020):
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
In: British Journal of Cancer, Bd. 122, Nr. 9: S. 1324-1332
2016
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe und Piccart-Gebhart, Martine
(2016):
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 3: S. 357-366